Curis, Inc.

CRIS ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Income Statement
Annual Quarterly

Income Statement

Line Item FY2009
Revenue $8.6M
Cost of Revenue —
Gross Profit —
Gross Margin —
Operating Expenses
Research & Development $9.9M
SG&A Expense $8.7M
Operating Income $-10.0M
Operating Margin -116.9%
Interest Expense —
Pretax Income —
Income Tax Expense —
Net Income $-9.8M
Net Margin -114.4%
EPS (Basic) $-0.08
EPS (Diluted) $-0.08
Shares Outstanding (Basic) —
Shares Outstanding (Diluted) —
Dividends Per Share —
← Newer Page 3 of 3 Older →